张 贝,苏是苍

前列腺癌（prostatic cancer，PCa）发病率在男性肿瘤中位居前列，但因其早期缺乏特征性的临床表现，确诊时已多为中晚期，总体预后不佳。核磁共振（magnetic resonance imaging，MRI）仍是目前最常用的显像方法，前列腺癌诊疗指南中推荐使用前列腺特异性膜抗原（prostate specific membrane antigen，PSMA）正电子发射计算机断层与计算机断层（positron emission tomography/computed tomography，PET/CT）显像联合多参数MRI以进一步提高前列腺癌的检出率，PSMA显像在前列腺癌的诊断、分期及复发监测等各方面的研究也发挥了其优势，取得了较好的结果。在过去68Ga标记的显像剂在临床应用更多，但因18F更优化的显像性能，近几年对于18F标记的PSMA显像剂的研究也逐渐增多，18F-DCFPyL就是其中一种，结果也表明18F-DCFPyL PET/CT显像在前列腺癌的定位、分期以及再分期、疗效监测中同样表现优良，在提供准确诊断信息的同时也使治疗管理方案更优化，本文就18F-DCFPyL PET/CT在前列腺癌诊疗中的应用价值进行综述。

18F-DCFPyL；PET/CT；前列腺癌；分期；复发监测

[1]Rawla P,Epidemiology of prostate cancer[J].World J Oncol.2019;10:63–89. [2]Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135(5): 584-590. [3]Yip K, Li Y, Chen S, et al.68Ga-PSMA PET/CT and mpMRI for primary lymph node staging of intermediate to high-risk prostate cancer: a systematic review and meta-analysis of diagnostic test accuracy[J]. Clin Transl Imaging, 2021, 9(5):523-537. [4]Hope T, Goodman J, Allen I E, et al. Meta analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology[J] .J. Nucl. Med, 2019, 60(6): 786-793. [5]Farolfi A, Gafita A, Calais J, et al. 68Ga-PSMA-11 positron emission tomography detects residual prostate cancer after prostatectomy in a multicenter retrospective study[J]. J Urol 2019;202: 1174-1181. [6]Demi R, Kol M, Aca R, Uca R, et al．Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process[J]. Prostate, 2015,75( 7) : 748－757. [7]Pan K, Wang J, Wang C, et al. Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer:A Meta-Analysis[J]. Frontiers in Oncology. 2021.10: 597422 [8]Zhang T, Yang S, Lin L, et al. Role of 18F-DCFPyL PET/CT in patients with suspected prostate cancer[J]. Hell J Nucl Med 2022; 25(1): 11-18. [9]Westphalen A, McCulloch C, Anaokar J, Arora S, Barashi N, Barentsz J, et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel[J]. Radiology. 2020;296(1):76–84. [10]Bodar Y, Jansen B, Meijer D, et al. Detection of prostate cancer with 18F‑DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA‑targeted biopsy feasible? The detect trial[J]. World Journal of Urology (2021) 39:2439–2446. [11]Nguyen T, Bhosale P, Xu G, et al. Comparison of PSMA-based 18F-DCFPyL PET/CT and pelvic multiparametric MRI for lesion detection in the pelvis in patients with prostate cancer.[J] Am J Nucl Med Mol Imaging 2022;12(6):166-179. [12]Liu Y, Dong Y, Liu J, et al. Comparison between 18F‐DCFPyL PET and MRI for the detection of transition zone prostate cancer[J]. The Prostate. 2021;81:1329–1336. [13] Hu X, Cao Y, Ji B, et al . Comparative study of 18F-DCFPyL PET/CT and 99mTc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer[J].Front. Med. 10:1201977. [14]Zhou S, Liu T, Zhu Z, et al. 18F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer[J]. Front. Oncol. 2022.12:800904 [15]Fourquet A, Rosenberg A, Mena E, et al. A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer [J]. J Nucl Med 2022; 63:735–741 [16]Gillessen S, Attard G, Beer T, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[J]. Eur Urol 2020;77(4):508–547. [17]A.Cahid Civelek. Management of Metastatic Prostate Cancer Biochemical Recurrence with Use of 18F-DCFPyL PET/CT[J]. Radiology 2022; 303:423–424 [18]Sun J, Lin Y, Wei X, et al. Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis[J]. Front. Oncol. 2021.11:649171 [19]Metser U, Zukotynski K, MSc V, et al. Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial[J]. Radiology. 2022;303:414–422 [20]Chaussé C, Ben-Ezra N, Stoopler M, et al. Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis[J]. Can Urol Assoc J 2021;15(6):173-8. 21.Ulaner C, Thomsen B, Bassett J, et al. 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer:Prospective Trial with Pathologic Confirmation[J]. Radiology 2022; 305:419–428 [22]Meijer D, Leeuwen P, Oosterholt P, et al. Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study[J]. European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:2960–2969. [23]Liu W, Zukotynski K, Emmett L, et al. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy[J]. International Journal of Radiation Oncology Biology Physics 2020.106(3):546-555 [24]Jansen B, Cysouw M, Vis A, et al. Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer[J]. J Nucl Med 2020; 61:1320–1325.

点击下载PDF